参考文献/References:
[1] Emami M, Morton JB, Chan KH, et al. Catheter ablation of post-infarct VT:mechanisms, strategies and outcomes[J]. Heart L ung Circ,2019,28(1):76-83.
[2] Raul W, Knight BP, Gold MR, et al. Safety and efficacy of a totally subcutaneous implantable-cardioverter defibrillator[J]. Circulation,2013,128(9):944-953.
[3] Burke MC,Gold MR,Knight BP,et al. Safety and efficacy of the totally subcutaneous implantable defibrillator: 2-year results from a pooled analysis of the IDE?study?and?EFFORTLESS registry[J]. J Am Coll Cardiol,2015,65(16):1605-1615.
[4] Dev S,Peterson PN,Wang Y,et al. Prevalence,correlates,and temporal trends in antiarrhythmic drug use at discharge after implantable cardioverter defibrillator placement(from the National Cardiovascular Data Registry[NCDR]) [J]. Am J Cardiol,2014,113(2): 314-320.
[5] Saxon LA,Hayes DL,Gilliam FR,et al. Long-term outcome after ICD and CRT implantation and influence of remote device follow-up:the ALTITUDE survival study[J]. Circulation,2010,122(23):2359-2367.
[6] Bardy GH,Lee KL,Mark DB,et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure[J]. N Engl J Med,2005,352(3):225-237.
[7] Connolly SJ,Dorian P,Roberts RS,et al. Comparison of beta-blockers,amiodarone plus beta-blockers,or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study:a r andomized trial[J]. JAMA,2006,295(2):165-171.
[8] Wolkove N, Baltzan M. Amiodarone pulmonary toxicity[J]. Can Respir J,2009,16(2):43-48.
[9] Patel D,Hasselblad V,Jackson KP,et al. Catheter ablation for ventricular tachycardia(VT) in patients with ischemic heart disease:a systematic review and a meta-analysis of randomized controlled trials[J]. J I nterv Card E lectrophysiol,2016,45(2):111-117.
[10] Vergara P,Trevisi N,Ricco A,et al. Late potentials abolition as an additional technique for reduction of arrhythmia recurrence in scar related ventricular tachycardia ablation[J]. J C ardiovasc Electrophysiol,2012,23(6):621-627.
[11] Reddy VY,Reynolds MR,Neuzil P,et al. Prophylactic catheter ablation for the prevention of defibrillator therapy[J]. N Engl J Med,2007,357(26):2657-2665.
[12] Bunch TJ,Weiss JP,Crandall BG,et al. Patients treated with catheter ablation for ventricular tachycardia after an ICD shock have lower long-term rates of death and heart failure hospitalization than do patients treated with medical management only[J]. Heart R hythm,2014,11(4):533-540.
[13] Zipes DP,Camm AJ,Borggrefe M,et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death:a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines(Writing Committee to Develop guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society[J]. Europace,2006,8(9):746-837.
[14] Klemm HU,Ventura R,Steven D,et al. Catheter ablation of multiple ventricular tachycardias after myocardial infarction guided by combined contact and noncontact mapping[J]. Circulation,2007,115(21):2697-2704.
[15] Bogun F,Kim HM,Han J,et al. Comparison of mapping criteria for hemodynamically tolerated,postinfarction ventricular tachycardia[J]. Heart Rhythm,2006,3(1):20-26.
[16] Khaykin Y, Skanes A,Whaley B,et al. Real-time integration of 2D intracardiac echocardiography and 3D electroanatomical mapping to guide ventricular tachycardia ablation[J]. Heart Rhythm,2008,5(10):1396-1402.
[17] Chauhan VS,Nair GM,Sevaptisidis E,et al. Magnetoelectroanatomic mapping of arrhythmias in structural heart disease using a novel multielectrode catheter[J]. Pacing Clin E lectrophysiol,2004,27(8):1077-1084.
[18] Patel AM,d’Avila A,Neuzil P,et al. Atrial tachycardia after ablation of persistent atrial fibrillation:identification of the critical isthmus with a combination of multielectrode activation mapping and targeted entrainment mapping[J]. Circ Arrhyth Electrophysiol,2008,1(1):14-22.
[19] Stevenson WG,Wilber DJ,Andrea N,et al. Irrigated radiofrequency catheter ablation guided by electroanatomic mapping for recurrent ventricular tachycardia after myocardial infarction:the multicenter thermocool ventricular tachycardia ablation trial[J]. Circulation,2008,118(25):2773.
[20] Tanner H,Hindricks G,Volkmer M,et al. Catheter ablation of recurrent scar-related ventricular tachycardia using electroanatomical mapping and irrigated ablation technology:results of the prospective multicenter Euro-VT-study[J]. J Cardiovasc E lectrophysiol,2010,21(1):47-53.
[21] Aliot EM,Stevenson WG,Almendral-Garrote JM,et al. EHRA/HRS Expert Consensus on Catheter Ablation of Ventricular Arrhythmias:developed in a partnership with the European Heart Rhythm Association(EHRA),a Registered Branch of the European Society of Cardiology(ESC),and the Heart Rhythm Society(HRS);in collaboration with the American College of Cardiology(ACC) and the American Heart Association(AHA)[J]. Europace,2009,11(6):771-817.
[22] Karl-Heinz K,Anselm S,Lars E,et al. Catheter ablation of stable ventricular tachycardia before defibrillator implantation in patients with coronary heart disease(VTACH):a multicentre randomised controlled trial[J]. Lancet,2010,375(9708):31-40.
[23] Priori SG,Blomstrom-Lundqvist C,Mazzanti A,et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death:The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology(ESC)Endorsed by:Association for European Paediatric and Congenital Cardiology(AEPC)[J]. Europace,2015,17(11): 1601-1687.
[24] Sapp JL,Wells GA,Parkash R,et al. Ventricular tachycardia ablation versus escalation of antiarrhythmic drugs[J]. N Engl J Med,2016,375(2):111-121.
[25] Al-Khatib SM,Daubert JP,Anstrom KJ,et al. Catheter ablation for ventricular tachycardia in patients with an implantable cardioverter defibrillator(CALYPSO) pilot trial[J]. J Cardiovasc Electrophysiol,2015,26(2): 151-157.
[26] Tung R,Vaseghi M,Frankel DS,et al. Freedom from recurrent ventricular tachycardia after catheter ablation is associated with improved survival in patients with structural heart disease:an International VT Ablation Center Collaborative Group study [J]. Heart Rhythm,2015,12(9):1997-2007.
[27] Al-Khatib SM,Stevenson WG,Ackerman MJ,et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death[J]. Circulation,2018,138(13):e272-e391.
[28] Morawski S,Pruszkowska P,Sredniawa B,et al. Long-term outcome of catheter ablation and other form of therapy for electrical storm in patients with implantable cardioverter-defibrillators[J]. J Interv C ard E lectrophysiol,2017,50(3):227-234.
[29] Kumar S,Fujii A,Kapur S,et al. Beyond the storm:comparison of clinical factors,arrhythmogenic substrate,and catheter ablation outcomes in structural heart disease patients with versus those without a history of ventricular tachycardia storm[J]. J C ardiovasc E lectrophysiol,2017,28(1):56-67.
[30] Kuck KH,Tilz RR,Deneke T,et al. Impact of Substrate Modification by Catheter Ablation on Implantable Cardioverter-Defibrillator Interventions in Patients With Unstable Ventricular Arrhythmias and Coronary Artery Disease: Results From the Multicenter Randomized Controlled SMS(Substrate Modification Study)[J]. Circ Arrhyth Electrophysiol,2017,10(3):e004422.
[31] Cronin EM,Bogun FM,Maury P,et al. 2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias[J]. J A rrhyth,2019,35(3):323-484.
[32] Wasmer K,Eckardt L. 3-D mapping and ablation of recurrent ventricular tachycardia in patients with ischemic cardiomyopathy[J]. Herzschrittmacherther Elektrophysiol,2017,28(2):199-205.
[33] Mahida S,Sacher F,Dubois R,et al. Cardiac imaging in patients with ventricular tachycardia[J]. Circulation,2017,136(25):2491-2507.
[34] Dickfeld T,Tian J,Ahmad G,et al. MRI- guided ventricular tachycardia ablation:integration of late gadolinium-enhanced 3D scar in patients with implantable cardioverter-defibrillators[J]. Circ Arrhyth Electrophysiol,2011,4(2):172-184.
[35] 刘启明.器质性心脏病室性心动过速导管消融治疗进展[J].心血管病学进展,2011,32(3):297-299.
[36] Aziz Z,Shatz D,Raiman M,et al. Targeted ablation of ventricular tachycardia guided by wavefront discontinuities during sinus rhythm[J]. Circulation,2019,140(17):1383-1397.
[37] 何淼,杜文娟. 经CARTO三维电标测系统治疗复杂型心律失常的研究现状[J]. 心血管病学进展,2018,39(2):243-247.
[38] Mallidi J,Nadkarni GN,Berger RD,et al. Meta-analysis of catheter ablation as an adjunct to medical therapy for treatment of ventricular tachycardia in patients with structural heart disease[J]. Heart Rhythm,2011,8(4):503-510.
[39] Soucek F,Starek Z. Use of bipolar radiofrequency catheter ablation in the treatment of cardiac arrhythmias[J]. Curr Cardiol Rev,2018,14(3):185-191.
[40] Sapp JL,Cooper JM,Soejima K,et al. Deep myocardial ablation lesions can be created with a retractable needle-tipped catheter[J]. Pacing Clin E lectrophysiol,2004,27(5):594-599.
[41] Stevenson WG,Tedrow UB,Reddy V,et al. Infusion needle radiofrequency ablation?for treatment of refractory?ventricular arrhythmias[J]. J Am Coll Cardiol,2019,73(12):1413-1425.
[42] di Monaco A,Quadrini F,Troisi F,et al. Cardiopulmonary support in patients undergoing catheter ablation of poorly tolerated ventricular arrhythmias and electrical storm[J]. J Cardiovasc Electrophysiol,2019,30(8):1281-1286.
[43] Santangeli P,Ellenbogen KA. Update on catheter ablation research from The 2019 European Heart Rhythm Association Congress[J]. J Cardiovasc Electrophysiol,2019,30(8):1187-1190.
相似文献/References:
[1]王铁华,郑景辉,莫云秋.蛋白质组学在心肌梗死中的研究进展[J].心血管病学进展,2015,(5):616.[doi:10.3969/j.issn.1004-3934.2015.05.024]
WANG Tiehua,ZHENG Jinghui,MO Yunqiu.Research Progress of Proteomics in Myocardial Infarction[J].Advances in Cardiovascular Diseases,2015,(5):616.[doi:10.3969/j.issn.1004-3934.2015.05.024]
[2]孙洋.基质金属蛋白酶与心肌梗死后心脏重构[J].心血管病学进展,2019,(8):1094.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.006]
SUN Yang.Matrix Metalloproteinases in Cardiac Remodeling after Myocardial Infarction[J].Advances in Cardiovascular Diseases,2019,(5):1094.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.006]
[3]陈丰 苏强 朱继金.高迁移率族蛋白B1在心脏炎症反应性疾病中的研究进展[J].心血管病学进展,2019,(8):1111.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.010]
CHEN Feng,SU Qiang,ZHU Jijin.Research Progress of HMGB1 in Myocardial Inflammatory Reactivity Disease[J].Advances in Cardiovascular Diseases,2019,(5):1111.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.010]
[4]常文婧 王丽娜.Hippo通路在心脏发育、再生和疾病中的作用[J].心血管病学进展,2019,(8):1115.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.011]
CHANG Wenjin,WANG Lina.Role of Hippo Pathway in Heart Development,Regeneration and Disease[J].Advances in Cardiovascular Diseases,2019,(5):1115.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.011]
[5]王宇 周思维 张莎 吴弘.植入型心律转复除颤器在心肌梗死后心脏性猝死中的研究进展[J].心血管病学进展,2020,(1):4.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.002]
WANG Yu,ZHOU Siwei,ZHANG Sha,et al.Implantable Cardioverter Defibrillator in Sudden Cardiac Death after Myocardial Infarction[J].Advances in Cardiovascular Diseases,2020,(5):4.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.002]
[6]邹先明 赵然尊.长链非编码RNA ANRIL与心血管疾病的研究进展[J].心血管病学进展,2020,(2):167.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.017]
ZOU Xianming,ZHAO Ranzun.Long Non-Coding RNA ANRIL and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2020,(5):167.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.017]
[7]王茜 李晶洁.细胞学机制在调控心肌梗死后炎症反应中的研究进展[J].心血管病学进展,2020,(2):190.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.023]
WANG QianLI Jingjie.Cytological Mechanisms in Regulation of The Post-infarction Inflammatory Response[J].Advances in Cardiovascular Diseases,2020,(5):190.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.023]
[8]黄柳,张瑞宁,田小超,等.内皮祖细胞与冠心病患者CD14CD16+单核细胞共培养后移植心肌梗死大鼠对血管密度及心肌梗死面积的影响[J].心血管病学进展,2020,(2):203.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.027]
HUANG Liu,ZHANG Ruining,TIAN Xiaochao,et al.Effects of Co-cultured Endothelial Progenitor Cells and CD14++CD16+ Monocytes from Coronary Heart Disease Patients on Vascular Density and Myocardial Infarction Size in Transplanting Myocardial Infarction Rats[J].Advances in Cardiovascular Diseases,2020,(5):203.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.027]
[9]刘玉婷,贾锋鹏.骨膜蛋白与心血管疾病的研究进展[J].心血管病学进展,2020,(3):239.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.006]
LIU Yuting,JIA Fengpeng.Roles of Periostin in Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2020,(5):239.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.006]
[10]谢建华,赵鸿泽,刘剑雄.MicroRNA在心肌梗死后左室重塑和心力衰竭发展中的研究现状[J].心血管病学进展,2020,(3):259.[doi:10.16806 /j.cnki.issn.1004-3934.2020.03.011]
XIE Jianhua,ZHAO Hongze,LIU Jianxiong.MicroRNA in Development of Left Ventricular Remodeling and Heart Failure after Myocardial Infarction[J].Advances in Cardiovascular Diseases,2020,(5):259.[doi:10.16806 /j.cnki.issn.1004-3934.2020.03.011]
[11]王思博 王连生.心肌梗死后室性心律失常的治疗进展[J].心血管病学进展,2021,(6):481.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.001]
WANG SiboWANG Liansheng.Treatment of Ventricular Arrhythmias after Myocardial Infarction[J].Advances in Cardiovascular Diseases,2021,(5):481.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.001]